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ABSTRACT
Background: Childhood pneumonia is one of the major causes of under-five mortality in developing countries. Any interventions which 
can reduce the mortality and morbidity of pneumonia are of great importance. Adjuvant zinc therapy is one such intervention studied 
in various parts of the world with inconclusive results. Objective: We aim to study the impact of a single dose of zinc therapy on the 
outcome of childhood severe pneumonia. Material and Methods: Randomized, placebo-controlled study of young children between 
2 and 24 months was conducted to study the impact of single dose zinc administration on time to resolution of severe pneumonia. The 
subjects were assigned two groups, zinc group and non-zinc group, by stratified randomization. The zinc group received unlabeled oral 
zinc syrup 20 mg of elemental zinc as single dose for children >6 months of age and 10 mg of elemental zinc as single dose for children 
<6 months. The non-zinc group children were administered unlabeled non-zinc containing placebo as single dose. Results: From April 
2011 to December 2011, 1284 children screened for pneumonia as per Integrated Management of Neonatal and Childhood Illnesses 
guidelines and 126 children were included in the study. Of these 126 children, 63 were randomized to receive zinc and 63 to receive 
placebo. The mean duration of respiratory distress before hospitalization was 1.4±0.5 days in zinc group as compared to 1.1±0.5 days in 
non-zinc group (p=0.001). The mean duration of resolution of distress was 52.47±33.99 h in zinc group as compared to 74.17±37.76 h in 
the non-zinc group (p=0.05). Similarly, the mean duration for resolution of symptoms was 65.52±36.03 h in zinc group as compared to 
88.00±37.97 in non-zinc group (p=0.05). The 23% of the children in non-zinc group had treatment failure (p=0.03). Conclusion: Single 
dose of adjuvant oral zinc therapy in severe pneumonia, reduces the duration of respiratory distress, resolves the symptoms early and 
decreases the incidence of treatment failure. However, the total duration of hospitalization was not affected by zinc therapy.
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The estimated number of deaths globally in children aged <5 years was 6.6 million in 2012. 22% of these under 5 deaths occur in India. The leading causes of death 
among children under 5 years of age include pneumonia (17%), 
pre-term birth complications (15%), intrapartum complications 
(10%), diarrhea (9%), and malaria (7%) [1]. Interventions 
which can prevent or reduce the morbidity of pneumonia are of 
great importance to improve the childhood survival.
Zinc deficiency is common among children in low-income 
countries due to a variety of factors such as low food intake, 
particularly from animal sources; limited zinc bioavailability 
from local diets; and loss of zinc during recurrent diarrheal 
illnesses. Zinc deficiency is associated with immunodeficiency 
and increased rates of serious infectious diseases. The deficiency 
is widely recognized as contributing to the limited growth of 
children in both low-income and high-income countries [2].
It is estimated that zinc deficiency in association with 
diarrhea, pneumonia, and malaria contributes to 4.4% of deaths 
and 3.8% of lost disability-adjusted life years among children 
aged 6-59 months in Africa, Latin America, and Asia [3]. In a 
meta-analysis of clinical trials evaluating, the preventive role of 
zinc as a daily supplementation led to 14% and 8% reductions in 
the risk of diarrhea and pneumonia, respectively [4]. The World 
Health Organization now recommends zinc for the treatment of 
children with diarrhea [5] because there is sufficient evidence 
demonstrating that supplementation reduces the severity and 
duration of the episode [6]. The benefit of zinc in the treatment 
of pneumonia is, however, unclear. Although zinc as adjuvant 
therapy for hospitalized children with pneumonia was found 
to be beneficial in one clinical trial in Bangladesh [7], but 
other trials in India [8] and Australia [9,10] found no effect. 
Whether zinc administration has a beneficial effect when 
given to children hospitalized with severe pneumonia needs to 
be clarified. As the outcome has to be measured even before 
completion of this adjuvant therapy, the utility of longer 
duration of therapy is debatable. To address these two issues, 
we studied the impact of single dose oral zinc therapy on the 
outcome of children hospitalized with severe pneumonia.
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MATERIAL AND METHODS
This was a randomized, placebo-controlled trial in young 
children between 2 and 24 months designed to measure the 
impact of single dose zinc administration on time to resolution 
of severe pneumonia. An important secondary outcome was the 
risk of treatment failure. Clearances were obtained from the 
Ethical Board of the Indira Gandhi Institute of Child Health 
(IGICH), Bengaluru, India.
Children aged 2-24 months presenting to the IGICH 
with complaints of a cough lasting <14 days and/or difficult 
breathing of <72 h duration with lower chest indrawing (LCI) 
were screened and classified as per the Integrated Management 
of Neonatal and Childhood Illnesses (IMNCI) algorithm [11]. 
Children with severe pneumonia were included in the study. 
Children with other co-morbid conditions which predisposes 
to recurrent and or severe pneumonia-like neuromuscular 
disorders, recurrent aspiration syndromes, congenital heart 
disease, children with multisystem diseases, congenital lung 
malformations, nosocomial infections, primary or secondary 
immunodeficiency were excluded. Children with recurrent 
wheezing (defined as three episodes over the past 6 months 
and on treatment with bronchodilators), disappearance of LCI 
after nebulized salbutamol, severe wasting, severe anemia 
(hemoglobin 7 g/dL), documented tuberculosis, children 
who has received antibiotics for the same illness before 
hospitalization or concomitant diarrhea with dehydration were 
also excluded. We also excluded children who were receiving 
medication containing zinc.
Eligible children were initially assessed for hypoxia using 
pulse oximeter and presence of wheezing. Oxygen saturation 
(SpO2) was recorded twice after stabilization of the reading 
for 1 min. The higher of the two readings was used. For 
children with SpO2 of <90%, oxygen was provided before 
further evaluation. Children with wheezing were given up to 
three doses of nebulized salbutamol 20 min apart, reassessed, 
and excluded if LCI disappeared. A history of the child’s 
illness was taken, and physical examination carried out by a 
standardized form. Children were weighed using an electronic 
scale (sensitivity ±5 g). The recumbent length of the children 
was measured by an infantometer. Stunting (defined as length-
for-age <2 Z score) and wasting (weight-for-length <2 Z score) 
were calculated using 2009 WHO Child Growth Standards [12].
Complete hemogram, acute phase reactants (serum 
C - reactive protein, quantitative), and blood culture were 
obtained at the baseline. A chest radiograph taken in all children 
was interpreted by a radiologist to rule out complications. 
Informed consent was obtained for eligible children from their 
parents or guardian after explaining the study protocol.
These eligible children were given the first dose of 
intravenous antibiotics. They were divided into two group by 
stratified randomization into zinc group and non-zinc group. 
The zinc group was administered unlabeled oral zinc syrup 
20 mg of elemental zinc as single dose for children above 
6 months of age and 10 mg of elemental zinc as single dose 
for children <6 months. The non-zinc group children were 
administered unlabeled non-zinc containing placebo as single 
dose. These were administered by the person who was not 
involved in the study. These syrups were administered through 
naso-gastric tube for those children who were not able to take 
orally. These children were observed for 20 min after the 
administration of these syrups for vomiting. For children who 
vomited within 20 min of administration of syrups, the dose 
was repeated with close monitoring.
Enrolled children were admitted to the hospital and 
monitored by pediatricians involved in the study at 8 hourly 
intervals until discharge. Amoxicillin-clavulanic acid (75 mg/
kg/day intravenously in two divided doses) were given until 
clinical improvement, defined as the absence of danger signs, 
no episode of hypoxia for 24 consecutive h and no evidence 
LCI for a 48-h period. Patients were then discharged with 
advice to continue oral amoxicillin-clavulanic acid to complete 
treatment of a total duration of 10 days.
Antibiotics were changed to ceftriaxone in children who 
failed to improve, defined as persistence of LCI or of any 
danger signs despite 48 h of treatment or appearance of new 
danger signs or hypoxia with the deterioration of patient’s 
clinical status any time after initiation of treatment. A decision 
to change antibiotics was made only after consultation with 
senior pediatricians involved in the study. For children unable 
to eat/drink or breastfeed, intravenous fluids based on daily 
requirements were initiated. Humidified oxygen was given to 
children with documented hypoxia.
During each physician visit, SpO2 was documented after a 
washout period of 5-min and oxygen discontinued when they 
were no longer hypoxic. The absence of hypoxia was confirmed 
after a second reading taken 30 min later. Every 8 hourly, 
axillary temperature, respiratory rate, LCI, and wheezing and 
crepitations on auscultation were recorded by two independent 
pediatricians separately. Their findings were matched against 
those of an experienced pediatrician until the desired agreement 
was reached.
Outcome measurements
The primary outcome, time to resolution of severe pneumonia, 
was defined as the period starting from enrollment to the 
beginning of a 24-h consecutive period of absence of LCI, 
hypoxia, and any danger signs as per IMNCI [11]. The secondary 
outcome, treatment failure, was defined as a requirement for a 
change in antibiotics, development of complications, such as 
empyema or pneumothorax requiring surgical intervention, or 
requirement of ventilatory or inotropic support.
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Statistical analysis
Student’s t-test (two-tailed, independent) has been used to find 
the significance of study parameters on a continuous scale 
between two groups. Chi-square/Fisher exact test has been used 
to find the significance of study parameters on a categorical 
scale between two or more groups.
RESULTS
From April 2011 to December 2011, we screened 1284 children 
meeting inclusion criteria. Of these, 1158 (90%) children were 
not eligible for inclusion due to various reasons as shown in 
Fig. 1. After enrollment of the remaining 126 children, 63 were 
randomized to receive zinc and 63 to receive placebo (Fig. 1).
In the non-zinc group, 66.7% of the children were aged 
between 2 and 12 months. This was statistically significant 
(p=0.03). Other baseline demographic parameters were 
comparable in both groups (Table 1). Mean duration of 
respiratory distress before hospitalization was 1.4±0.5 days 
in zinc group as compared to 1.1±0.5 days in non-zinc group 
which was statistically significant (p=0.001). Severe respiratory 
distress (respiratory rate >60/min) was found in 70% of infants 
in the zinc group as against 35.7% of infants in the non-zinc 
group (p=0.004). Auscultatory crepitations were seen in 90.4% 
of the children in non-zinc group as compared 30.1% of the 
children in non-zinc group (<0.001) (Table 2).
Analyzes were done by intention to treat. The mean 
duration of resolution of distress was 52.47±33.99 h in zinc 
group as compared to 74.17±37.76 h in non-zinc group which 
was statistically significant (p=0.0493). Similarly, mean 
duration for resolution of symptoms was 65.52±36.03 h in zinc 
group as compared to 88.00±37.97 in non-zinc group (0.0491). 
However, there was no statistically significant difference 
in other outcome indicators such as mean duration for the 
disappearance of danger signs, to reach SpO2 of >90% in room 
air and of hospital stay among both groups. 23% of the children 
in the non-zinc group as against 9.5% of the children in zinc 
group had treatment failure (Table 3).
DISCUSSION
This study was conducted to determine the impact of the single 
dose oral zinc therapy as adjunct therapy on the outcome of severe 
pneumonia in children. In the literature available so far, varying 
duration of oral zinc as adjuvant therapy in childhood severe 
pneumonia has been used to study its impact on the outcome 
of pneumonia. However, the outcome has to be measured even 
before completion of this adjuvant therapy, and the utility of 
longer duration of therapy is debatable. Hence, we studied the 
impact of single dose oral zinc therapy as compared to varying 
longer duration of therapy used in various other studies.
Figure 1: Trial profile of a randomized, placebo-controlled study of single dose oral zinc as adjunct therapy for severe pneumonia 
in children aged 2-24 months of age
Table 1: Baseline demographic parameters
Characteristics Zinc group Non-zinc group p value
n Value (%) n Value (%)
Age (months)
2-12 30 47.6 42 66.7 0.03
13-24 33 52.4 21 33.3
Mean age 
(in months)
63 15.33±5.98 63 13.57±7.05 0.13
Male 42 66.7 42 66.7 1.00
Female 21 33.3 21 33.3
Rural 15 23.8 18 28.5 0.54
Urban 48 76.1 45 71.4
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This study shows a significant impact of single dose of 
adjuvant oral zinc therapy in reducing the duration of respiratory 
distress, resolution of symptoms, and incidence of treatment 
failure. This impact of single dose oral zinc therapy on the early 
resolution of respiratory distress and reduction in the incidence 
of treatment failure is even more significant considering the 
fact that zinc group included the children who had significantly 
longer duration of pre-hospitalization illness and significantly 
higher number of infants with severe pneumonia at the time of 
admission. However, the non-zinc group included significantly 
higher number of infants who are expected to have prolonged 
and severe disease which can be a confounding factor.
Furthermore, the children who received zinc therapy had 
modest, but not significant, decrease in duration for resolution 
of danger signs and shorter duration of oxygen dependency 
and hospital stay when compared to the children who had not 
received adjuvant zinc therapy.
In a study undertaken in Nepal, children who received 
single daily dose of zinc for 14 days recovered faster, and fewer 
had treatment failure [10]. A study of 120 Iranian children 
hospitalized with severe pneumonia randomized into two 
groups with oral zinc administered for 7 days, and a placebo 
showed a significant decrease in the hospital stay as well as 
the resolution of symptoms in zinc receiving children [13]. 
This is comparable to our study where children receiving zinc 
recovered faster and had fewer treatment failures.
In a large multicentric study from New Delhi, India showed 
no overall benefit of the addition of zinc to antibiotics in reducing 
the time to recovery from pneumonia but showed a possible 
benefit of zinc supplementation in a subgroup of children with 
very severe pneumonia [14]. The subgroup of children with 
very severe pneumonia in this study is comparable to our study 
which includes only children with severe pneumonia. However, 
a similar study conducted in Vellore, south India, showed no 
overall effect on the duration of hospitalization or of clinical 
signs associated with severe infection in young children 
hospitalized for severe pneumonia [8]. In this study, the dosage 
of zinc supplemented was 10 mg/day as compared to 20 mg/
day in our study. Furthermore, significantly higher number of 
children had wheeze in both groups as compared to our study.
A Ugandan study, which compared daily zinc therapy for 
7 days with placebo, showed no significant difference in time 
to normalization of the respiratory rate, temperature, and SpO2 
Table 2: Baseline clinical parameters
Characteristics Zinc 
group
Non-zinc 
group
p value
n Value n Value
Mean duration of cough 
(in days)
63 3.8±2.0 63 3.6±2.1 0.58
Mean duration of fever 
(in days)
63 3.1±1.8 63 3.4±1.6 0.32
Mean duration of 
tachypnea (in days)
63 1.4±0.5 63 1.1±0.5 0.001
Respiratory rate 
(breaths per minute)
2-12 months
50-60 9 30.0 27 64.3 0.004
>60 21 70.0 15 35.7
12-24 months
40-50 24 72.7 12 57.1 0.24
>50 9 27.3 9 42.9
SpO2 at room air (%)
<90 30 47.6 39 62.0 0.11
>90 33 52.3 24 38.0
Danger signs
Lethargy 18 28.5 15 23.8 0.54
Inability to drink 36 57.1 39 61.9 0.59
Convulsions 0 0.0 3 4.7 0.24
Stridor in calm child 6 9.5 6 9.5 1.00
Signs of severe pneumonia
Lower chest retraction 63 100 63 100 1.00
Nasal flaring 3 4.7 6 9.5 0.30
Grunting 3 4.7 3 4.7 1.00
Cyanosis 36 57.1 30 47.6 0.28
Auscultatory findings
Creptitations 19 30.1 57 90.4 <0.01
Wheeze 11 52.3 21 33.3 0.06
Bronchial breath sounds 6 9.5 9 14.2 0.58
SpO2: Oxygen saturation
Table 3: Comparison of outcome among zinc group 
subjects with non-zinc group subjects
Variables Zinc group Non-zinc 
group
p value
Mean duration for 
the disappearance of 
danger signs (in h)
43.3±41.54 62.8±44.21 0.246
Mean duration to 
reach SpO2>90 in 
room air (in h)
23.9±38.36 45.8±53.42 0.130
Mean duration for 
resolution of distress 
(in h)
52.47±33.99 74.17±37.76 0.0491*
Mean duration of 
hospital stay (in days)
6.14±3.55 7.14±3.57 0.37
Mean duration for 
the resolution of 
symptoms (in h)
65.52±36.03 88.00±37.97 0.0490*
No of children with 
treatment failure
6 (9.5%) 15 (23%) 0.03*
SpO2: Oxygen saturation, *Statistically significant
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between the two arms, but showed a significant decrease in the 
case fatality rate [15]. In our study also, oral zinc therapy has 
no significant impact on reducing the duration of the oxygen 
dependency. However, our study showed significant impact by 
reducing the respiratory distress early. This contrast could be 
due to older study population and the inclusion of HIV-infected 
children in the Ugandan study.
Another study from Nepal compared 64 children who 
received zinc (loading dose of 20 mg/day on 1st day followed 
by maintenance dose of 10 mg/day for 7 days) with 53 children 
receiving placebo. The study did not show a significant 
reduction in the duration of severe pneumonia or reduction in 
hospital stay for children given daily zinc supplementation [16]. 
In contrast to our study, the outcome measured (duration of 
severe pneumonia) was not well defined in this study.
However, the homogenization of treatment is a challenge 
in this study as well as similar studies elsewhere because an 
individual child with pneumonia requires different therapeutic 
approach with respect to the choice of antibiotics and duration 
of therapy depending on the host and agent factors.
CONCLUSION
Single dose oral zinc as an adjuvant therapy in the children 
hospitalized with severe pneumonia was found to significantly 
reduce the duration of severe pneumonia in spite of these 
children had a longer duration of pre-hospitalization illness 
and severe disease at the time of admission. However, the total 
duration of hospitalization was affected significantly.
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